热门资讯> 正文

Talaris Therapeutics GAAP每股收益为-0.86美元

2025-03-13 21:19

Talaris Therapeutics press release (NASDAQ:TRML): Q4 GAAP EPS of -$0.86.
Cash, cash equivalents and investments were $294.9 million as of December 31, 2024, as compared to $203.0 million as of December 31, 2023.

More on Talaris Therapeutics

Tourmaline Bio rises as Wedbush initiates with Outperform on lead asset
Seeking Alpha’s Quant Rating on Talaris Therapeutics
Historical earnings data for Talaris Therapeutics
Financial information for Talaris Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。